AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01678053 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: omeprazole (proton pump inhibitor)
Description: Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
Study NCT01679587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: 20 mg molidustat as a single tablet
Study NCT01679587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of matching placebo will be given in each treatment arm
Study NCT02494102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Atypical Psychomotor stimulant
Study NCT02494102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00474851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate + estrogens
Description: Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
Study NCT00474851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norethindrone acetate + placebo
Description: norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
Study NCT02963870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Security Plan
Description: This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
Study NCT02963870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Security Plan
Description: This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
Study NCT03483168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally sensitive pain education
Description: The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
Study NCT03483168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain education program
Description: For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators.
Study NCT04205396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Description: Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
Study NCT04205396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
Study NCT04205396 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Participants will complete baseline and outcome assessments and no intervention will be conducted.
Study NCT01378455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive computerized handwriting training program
Description: In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
Study NCT01378455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional handwriting training program
Description: The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
Study NCT00712985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PREVNAR 13®
Description: Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCC-TT
Description: Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCC-CRM
Description: Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MCC
Description: Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
Study NCT04000919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-DOPA
Description: L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
Study NCT04000919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT04000919 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Carbidopa
Description: Carbidopa (50mg)
Study NCT02099396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+lobaplatin
Study NCT02099396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+lobaplatin
Study NCT04846166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontally healthy group
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
Study NCT04846166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontitis
Description: : interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
Study NCT01553279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Vaccine
Description: Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
Study NCT00633516 — intervention group
Intervention type: DEVICE
Intervention: Optical Spectroscopy
Description: Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
Study NCT02341950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Hard
Description: The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
Study NCT00577902 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Head and neck cancer patients receiving chemoradiation
Study NCT03026855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP Gel and PRP Injection
Description: Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment.
Study NCT03596931 — intervention group
Intervention type: DRUG
Intervention: Statins (Cardiovascular Agents)
Description: Prescribed with statins
Study NCT01622374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures
Study NCT01622374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures
Study NCT01587586 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS 180 µg Q1W
Description: 48 doses, solution, 48 weeks
Study NCT01587586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 180 µg Q1W, 48 doses
Description: 48 doses, solution, 48 weeks
Study NCT01587586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 270µg Q1W, 48 doses
Description: 48 doses, solution, 48 weeks
Study NCT01587586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 450µg Q2W, 24 doses
Description: 24 doses, solution, 48 weeks
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
Study NCT00311311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
Study NCT01383798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg lactose per day for 6 weeks
Study NCT01383798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 100 mg per day of ferrous sulfate for 6 weeks
Study NCT05820867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Session Bilateral Mandibular Third Molar Extraction
Description: Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
Study NCT05820867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Session Bilateral Mandibular Third Molar Extraction
Description: Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
Study NCT01303705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
Study NCT00823940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1362885
Description: 5 - 100mg of GSK1362885 or placebo
Study NCT00823940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1362885
Description: 100 - 600mg or placebo
Study NCT04375527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04375527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04375527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02047448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist Counseling
Description: The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 (JP-1366 A mg)
Description: Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (JP-1366 B mg)
Description: Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 (JP-1366 C mg)
Description: Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 (JP-1366 D mg)
Description: Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 (JP-1366 E mg)
Description: Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6 (JP-1366 F mg)
Description: Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7 (JP-1366 G mg)
Description: Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 8 (JP-1366 H mg)
Description: Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT03383042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 9 (JP-1366 I mg)
Description: Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
Study NCT01130337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine [Xeloda]
Description: 1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
Study NCT01130337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 intravenous infusion day 1 of every cycle
Study NCT01130337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab [Herceptin]
Description: First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
Study NCT00616642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Given orally
Study NCT03632096 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
Study NCT03632096 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
Study NCT04027647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: 30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.